<div id="readability-page-1"><div>                                 <figure>                                                                                                                                                    <img src="https://imageproxy.pbkrs.com/https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2025/08/shutterstock_2376712525-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2025/08/shutterstock_2376712525-430x241.jpg"/>                                                                          <figcaption>The acquisition includes the FDA-approved capsules and a central nervous system discovery platform. Credit: NMK-Studio/Shutterstock.com.</figcaption>                                 </figure>                             </div>                                                     <p>Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio.</p>    <p>In June 2025, Supernus and Sage entered a definitive agreement for the acquisition, with Supernus offering $8.50 per share in cash (or an aggregate of $561m), plus a non-tradeable contingent value right of up to $3.50 per share, totalling $12 per share in cash, or $795m.</p>    <p>The acquisition follows Sage’s rejection of a $469m takeover offer from Biogen in January 2025, which was deemed significantly undervalued by Sage’s board of directors.</p>    <p>The acquisition brings Sage’s US Food and Drug Administration (FDA)-approved Zurzuvae (zuranolone) capsules and a central nervous system discovery platform under Supernus’ portfolio.</p>    <p>Zurzuvae is intended for treating postpartum depression.</p>    <p>The company expects to realise cost synergies of up to $200m annually and accretive financial results in 2026 due to the acquisition.</p><div>                           <div>               <p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>             </p>               <div>                  <p><span>GlobalData Strategic Intelligence</span></p><div id="gdm-form-wrapper">                                             <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>                     <p><span>By GlobalData</span>                            </p></div>           </div>              </div> </div>    <p>Moelis &amp; Company served as the exclusive financial advisor to Supernus, while Goldman Sachs advised Sage.</p>    <p>Legal counsel for Supernus was provided by Saul Ewing, and Kirkland &amp; Ellis represented Sage in the legal aspects of the transaction.</p>    <p>Supernus Pharmaceuticals CEO and president Jack Khattar stated: “Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue.</p>    <p>“With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026.”</p>                                            <div>                  <h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>                  <p>Gain the recognition you deserve! The <strong>Pharmaceutical Technology Excellence Awards</strong> celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p> <p><strong>Nominate Now</strong></p></div>                                                        </div>

SAGE

SUPN

<p>Supernus Pharmaceuticals has acquired Sage Therapeutics for $795 million, enhancing its neuropsychiatry portfolio with FDA-approved Zurzuvae capsules. The deal, which follows Sage's rejection of a lower offer from Biogen, is expected to yield annual cost synergies of up to $200 million and positive financial results by 2026. Supernus CEO Jack Khattar emphasized the strategic fit of Sage in diversifying revenue sources and strengthening their growth product lineup.</p>

Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics